Journals / Journal of Research in Veterinary Medicine / 2019 / Cilt: 38 - Sayı: 2

In vitro pharmacodynamics of a danofloxacin plus colistin combination against multidrug-resistant (MDR) Escherichia coli isolated from animals

Pages
24–30
Publication Date
2019-12-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The results of this study showed that danofloxacin+colistin combination can be reserved as an alternative drug combination against MDR E. coliin veterinary medicine.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:As an alternative antimicrobial combination, danofloxacin+colistin was used for the inhibition of multidrug resistant E. coli.
📊
Key Findings & Data:In synergism tests, danofloxacin+colistin was found highly synergistic (%87) against E. coliisolates from animal origin.
💡
Conclusion & Impact:The results of this study showed that danofloxacin+colistin combination can be reserved as an alternative drug combination against MDR E. coliin veterinary medicine.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Colistin · Danofloxacin · in vitro Pharmacodynamics

Abstract

As an alternative antimicrobial combination, danofloxacin+colistin was used for the inhibition of multidrug resistant E. coli. After evaluation of interaction between the drugs by fractional inhibitory concentration tests and time kill assays, antimicrobial activity of the combination was showed by in vitro pharmacodynamics tests (minimum bactericidal concentration and mutant prevention concentration). Post-antibiotic and post-antibiotic sub-MIC effects were also determined in this study. In synergism tests, danofloxacin+colistin was found highly synergistic (%87) against E. coliisolates from animal origin. The combination exerted bactericidal activity against all E. coliisolates and individual bactericidal activity of each compound was lower than the combination. The combination reduced mutant prevention concentration of danofloxacin and colistin up to 32 –fold. Post-antibiotic sub-MIC effects of the combination at all sub-MIC concentrations were significantly longer than the post-antibiotic effects of combination (p< 0.001), danofloxacin (p< 0.001) and colistin (p< 0.001). The results of this study showed that danofloxacin+colistin combination can be reserved as an alternative drug combination against MDR E. coliin veterinary medicine.

🔖

Cite This Article

CENGİZ, M., SAHİNTURK, P., HEPBOSTANCİ, G., AKALİN, H., SONAL, S. (2019). In vitro pharmacodynamics of a danofloxacin plus colistin combination against multidrug-resistant (MDR) Escherichia coli isolated from animals. Journal of Research in Veterinary Medicine, Cilt: 38 - Sayı: 2, 24–30. https://ajindex.com/articles/778576

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Sahinturk P, Arslan E, Buyukcangaz E, et al. High level fluoroquinolone resistance in Escherichia coli isolated from animals in Turkey is due to multiple mechanisms. Turk J Vet Anim Sci. 2016;40:214-218.
  2. Elemam A, Rahimian J, Doymaz MJ. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. Clin Microbiol. 2010;48(10):3558-3562.
  3. Betts JW, Phee LM, Hornsey M, Woodford N, Wareham DW. In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2014;58(6):3541–3546.
  4. Lee H, Roh KH, Hong SG, et al. In vitro synergistic effects of antimicrobial combinations on extensively drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii isolates. Ann Lab Med. 2016;36:138-144.
  5. D'Souza BB, Padmaraj SR, Rekha PD, Tellis RC, Prabhu S, Pothen P. In vitro synergistic activity of colistin and ceftazidime or ciprofloxacin against multidrug-resistant clinical strains of Pseudomonas aeruginosa. Microb Drug Resist. 2014;20(6):550-554. European Medicines Agency. Updated advice on the use of colistin products in animals 3 within the European Union: development of resistance 4 and possible impact on human and animal health. EMA 2016;231573. Cassir N, Rolain JM, Broqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol. 2014;5:551. Kempf I, Jouy E, Chauvin C. Colistin use and colistin resistance in bacteria from animals. Int J Antimicrob Agents. 2016;48:598–606.
  6. Cengiz M, Sahinturk P, Sonal S, Buyukcangaz E, Sen A, Arslan E. In vitro bactericidal activity of enrofloxacin against gyrA mutant and qnr-containing Escherichia coli isolates from animals. Vet Rec. 2013;172(18):474. Dosler S, Karaaslan E, Gerceker AA. Antibacterial and anti-biofilm activities of melittin and colistin, alone and in combination with antibiotics against Gram-negative bacteria. J Chemother. 2016;28(2):95-103.
  7. Wei W, Yang H, Hu L, Ye Y, Li J. Activity of levofloxacin in combination with colistin against Acinetobacter baumannii: In vitro and in a Galleria mellonella model. J Microbiol Immunol Infect. 2015;15:1684-1692.
  8. Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics. Eur J Clin Microbiol. 2003;22(4):203-221. Odenholt I. Pharmacodynamic effects of subinhibitory antibiotic concentrations. Int J Antimicrob Agents 2001;17:1-8.
  9. Bambeke FV, Pages JM, Lee VJ. Inhibitors of bacterial eff